CoChat

The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide

Gasbjerg, Lærke S., Rosenkilde, Mette M., Meier, Juris J., Holst, Jens J., Knop, Filip K. · 2023 · Diabetes, Obesity and Metabolism
Cited by 41

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Tirzepatide is a unimolecular co‐agonist of the glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors recently approved for the treatment of type 2 diabetes by the US Food and Drug Administration and the European Medicine Agency. Tirzepatide treatment results in an unprecedented improvement of glycaemic control and lowering of body weight, but the contribution of the GIP receptor‐activating component of tirzepatide to these effects is uncertain. In this review, we present the current knowledge about the physiological roles of the incretin hormones GLP‐1 and GIP, their receptors, and previous results of co‐targeting the two incretin hormone receptors in humans. We also analyse the molecular pharmacological, preclinical and clinical effects of tirzepatide to discuss the role of GIP receptor activation for the clinical effects of tirzepatide. Based on the available literature on the combination of GLP‐1 and GIP receptor activation, tirzepatide does not seem to have a classical co‐activating mode of action in humans. Rather, in vitro studies of the human GLP‐1 and GIP receptors reveal a biased GLP‐1 receptor activation profile and GIP receptor downregulation. Therefore, we propose three hypotheses for the mode of action of tirzepatide, which can be addressed in future, elaborate clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.15216

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 70

  1. 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  2. 10.1210/jc.2003-030738 · DOI · Paper page
  3. 10.2337/db08-0958 · DOI · Paper page
  4. 10.1186/s13063-019-3259-x · DOI · Paper page
  5. 10.1007/s10741-021-10106-9 · DOI
  6. 10.1016/S2468-1253(22)00198-4 · DOI
  7. 10.1016/S0140-6736(21)01324-6 · DOI · Paper page
  8. 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
  9. 10.1007/s00125-017-4450-9 · DOI · Paper page
  10. 10.1210/jc.76.4.912 · DOI · Paper page
  11. 10.1016/0167-0115(94)90136-8 · DOI · Paper page
  12. 10.1111/j.1365-2265.2008.03451.x · DOI · Paper page
  13. 10.1152/ajpendo.00665.2010 · DOI · Paper page
  14. 10.1152/ajpgi.1998.275.5.G984 · DOI · Paper page
  15. 10.14814/phy2.13102 · DOI
  16. 10.1210/jc.2013-3766 · DOI · Paper page
  17. 10.3389/fcell.2021.749607 · DOI · Paper page
  18. 10.1016/j.bone.2020.115553 · DOI
  19. 10.1002/jbmr.4308 · DOI
  20. 10.1530/EC-17-0015 · DOI · Paper page
  21. 10.2337/db11-1451 · DOI · Paper page
  22. 10.1016/j.peptides.2019.170224 · DOI · Paper page
  23. 10.1016/j.peptides.2022.170749 · DOI · Paper page
  24. 10.1016/j.bcp.2020.114001 · DOI · Paper page
  25. 10.1016/j.bcp.2018.01.040 · DOI
  26. 10.1074/jbc.M213179200 · DOI
  27. 10.1128/MCB.00256-14 · DOI · Paper page
  28. 10.1111/bph.13323 · DOI · Paper page
  29. 10.1016/j.cmet.2017.11.003 · DOI
  30. 10.2337/db21-0848 · DOI · Paper page
  31. Bergmann NC, 2022, Diabetes, Obesity and Metabolism, 18
  32. 10.1007/s00125-021-05547-8 · DOI
  33. 10.1210/clinem/dgac542 · DOI
  34. NovoNordisk, 2023, Financial Report for 1 January 2023 to 31 March 2023, 1
  35. 10.2337/db13-1455 · DOI · Paper page
  36. Stensen S, 2022, Endogenous glucose‐dependent insulinotropic polypeptide contributes to sitagliptin‐mediated improvement in β‐cell function in patients with type 2 diabetes, Diabetes, 71, 2209
  37. Nauck MA, 1993, Preserved incretin activity of glucagon‐like peptide 1 [7‐36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type‐2 diabetes mellitus, JClinInvest, 91, 301
  38. 10.2337/diabetes.50.11.2497 · DOI · Paper page
  39. Hoe B, 2022, Improved glycemic control in patients with type 2 diabetes improves beta cell actions of endogenous glucose‐dependent insulinotropic polypeptide, Diabetes, 71, 1
  40. Adriaenssens AE, 2020, The glucose‐dependent insulinotropic polypeptide signaling axis in the central nervous system, Peptides, 125, 170
  41. 10.2337/db13-1627 · DOI · Paper page
  42. 10.1530/EJE-21-0135 · DOI · Paper page
  43. 10.1210/jc.2015-3133 · DOI · Paper page
  44. 10.1016/j.beem.2004.08.007 · DOI
  45. 10.1111/jgh.13026 · DOI · Paper page
  46. Kanie T, 2021, Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis, Cochrane Database Syst Rev, 10, 1
  47. 10.2337/db12-0976 · DOI · Paper page
  48. 10.1161/HYPERTENSIONAHA.121.17852 · DOI
  49. 10.1016/j.peptides.2017.12.021 · DOI · Paper page
  50. Gabe MBN, 2022, GIP and GLP‐2 together improve bone turnover in humans supporting GIPR‐GLP‐2R co‐agonists as future osteoporosis treatment, Pharmacol Res, 176, 1
  51. EMEA/H/C/005620/0000, 2022, Assessment Report
  52. 10.2337/db23-127-OR · DOI
  53. 10.1038/s41401-021-00758-6 · DOI
  54. Zhao F, 2021, Structural insights into hormone recognition by the human glucose‐dependent insulinotropic polypeptide receptor, Elife, 10, 1
  55. 10.1073/pnas.2116506119 · DOI · Paper page
  56. 10.1111/dom.14572 · DOI · Paper page
  57. 10.1007/s40262-022-01140-3 · DOI · Paper page
  58. 10.1038/s41467-018-03941-2 · DOI · Paper page
  59. 10.1172/JCI140046 · DOI · Paper page
  60. 10.1172/JCI143199 · DOI
  61. 10.1210/jc.2004-2460 · DOI · Paper page
  62. 10.3389/fendo.2020.00178 · DOI · Paper page
  63. 10.1111/dom.13018 · DOI · Paper page
  64. Amgen, 2022, AMG 133 is a first‐in‐class investigational bispecific molecule that activates GLP‐1R and inhibits GIPR
  65. 10.1016/j.coph.2020.08.011 · DOI
  66. 10.1111/bph.13384 · DOI
  67. 10.1111/dom.14736 · DOI
  68. 10.1017/S0007114511005228 · DOI
  69. 10.1016/j.mce.2014.10.025 · DOI
  70. 10.1210/jc.2019-00008 · DOI · Paper page

Cited by

See all 41

Metadata

Authors
Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2023-08-08
Volume
25
Issue
11
Pages
3079-3092
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W4385663314
Cited by
41
References
62
FWCI
6.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.